InvestorsHub Logo
Followers 60
Posts 11526
Boards Moderated 0
Alias Born 07/16/2006

Re: None

Tuesday, 07/18/2017 8:22:12 AM

Tuesday, July 18, 2017 8:22:12 AM

Post# of 20689
Sales in the US were USD 820 million (-15% cc), mainly due to pricing pressure in retail generics. US Biopharma sales increased 2% (cc), as the continued double-digit growth of Zarxio was partly offset by the slowdown of Omnitrope and Glatopa 20mg.


I don't believe they are referring to a slowdown of Glatopa sales to Teva's product but more of Copaxones decrease in the MS world.